X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”

By Cynthia Hicks  |    January 25, 2022
A new large-scale survey of 20,000 Americans covering all states and Congressional districts shows a majority find health care coverage costs unreasonable and a top priority health care issue for...   Read More

ICYMI: New report demonstrates growing global impact of antimicrobial resistance

By Jocelyn Ulrich  |    January 24, 2022
New research published in The Lancet shows for the first time the global impact of antimicrobial resistance (AMR), which poses an increasingly serious threat to human health around the world. The...   Read More

CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings

By Brian Newell  |    January 21, 2022
The Congressional Budget Office (CBO) recently released a new report looking at trends in spending, prices and use of prescription drugs. While some politicians are trying to use the report to...   Read More

New data show continued decline in death rates for cancer patients related to treatment advances

By Andrew Powaleny  |    January 20, 2022
According to a new report from American Cancer Society (ACS), death rates for cancer patients in the United States continue to decrease. Each year, ACS details a range of incidence, mortality and...   Read More

Legislation threatens patent protections and future innovation

By Tom Wilbur  |    January 12, 2022
Recently introduced legislation, the “Restoring the America Invents Act (RAIA),” if enacted, would push the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office to grant...   Read More

New study finds more than half of brand medicine spending goes to the supply chain and others

By Brian Newell  |    January 7, 2022
More than half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders in 2020 according to a new analysis from the Berkeley Research Group (BRG). These new...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates